Skip to search formSkip to main contentSkip to account menu

lebrikizumab

Known as: Immunoglobulin G4, Anti-(Human Interleukin 13) (Human-Mouse Monoclonal MILR1444a Gamma-4-Chain), Disulfide with Human-Mouse Monoclonal MILR1444a Kappa-Chain, Dimer, MILR1444A, PRO301444 
A humanized monoclonal antibody against interleukin 13 (IL-13) with immunosuppressive and anti-asthmatic activities. Lebrikizumab binds to IL-13 and… 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (1)

Monoclonal Antibodies
antigen binding

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Targeting the interleukin-4 and interleukin-13 pathways in severe asthma: current knowledge and future needs
Purpose of review Severe asthma is a heterogeneous disease that can be classified into phenotypes and endotypes based upon… 
Review
2015
Review
2015
Emerging therapeutic options for the treatment of patients with symptomatic asthma.
Review
2015
Review
2015
Profile of lebrikizumab and its potential in the treatment of asthma
Interleukin (IL)-13 has been associated with multiple inflammatory features of asthma. It affects multiple cellular lines in… 
Review
2014
Review
2014
Future biologic therapies in asthma.
2014
2014
Future Biologic Therapies in Asthma
Review
2012
Review
2012
The pharmacological modulation of allergen-induced asthma
Aeroallergens are the most common triggers for the development of asthma. Recent birth cohort studies have identified viral… 
2011
2011
Attacks on asthma
The current standard of care for asthma leaves large numbers of sufferers at risk for severe exacerbations and even death. But… 
2011
2011
Variable loss of lung function in COPD.
Chronic obstructive pulmonary disease (COPD) is a large and increasing global health problem.1 Although cigarette smoking is the… 
2011
2011
Lebrikizumab treatment in adults with asthma.
To the Editor: Corren et al. (Sept. 22 issue)1 report that treatment with lebrikizumab was associated with improved lung function… 
Review
2007
Review
2007
Advances in environmental and occupational disorders in 2013.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)